Inequities in care and treatment for triple negative breast cancer patients
In this report CRA and Susan G. Komen (Komen) examine the extent to which policies associated with triple negative breast cancer (TNBC) treatment and care can...
Kirsten works with leaders in healthcare helping to develop business practices that lead to greater access to affordable medicines, positive public perception, and sustained profitability to support investment in the next generation of innovation.
Kirsten sat on the leadership team of Pfizer Inc’s $30 billion global innovative pharmaceutical business, where she led Strategy and Business Evaluation. Previously, Kirsten led Pfizer’s Global Policy team. She is a visiting scholar with the American Enterprise Institute, an Aspen Institute Health Innovator Fellow, and a senior advisor to Charles River Associates.
Kirsten recently climbed Mt. Kilimanjaro to raise $1.6 million for cancer research with a team of biotech CEOs and investors.